BCL2 and breast carcinoma: The development of breast carcinoma subtypes-in-mouse PDX models has helped the identification of small chemical inhibitors to PI3K (Lehmann et al., 2014), checkpoint kinase 1 (Ma et al., 2012), aurora kinase (Romanelli et al., 2012), BCL-2 family-BH3 mimetic (Whittle et al., 2015), and many other drugs approved for treatment of breast cancers (Zardavas et al., 2013).